Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fifty‐two week follow‐up safety and effectiveness results of dupilumab treatment of moderate‐to‐severe atopic dermatitis from a retrospective, multicentric series
Ricardo Ruíz‐Villaverde, J.J. Domínguez-Cruz, José Carlos Armario Hita, et al.
Dermatologic Therapy (2019), pp. e12931-e12931
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis
Anne‐Sofie Halling, Nikolai Loft, Jonathan I. Silverberg, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 1, pp. 139-147
Closed Access | Times Cited: 219
Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data
Linde E. M. de Wijs, Angela L. Bosma, Nicole S. Erler, et al.
British Journal of Dermatology (2019) Vol. 182, Iss. 2, pp. 418-426
Open Access | Times Cited: 78
Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review
Nicoleta Neagu, Caterina Dianzani, Gianluca Avallone, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 6, pp. 820-835
Open Access | Times Cited: 49
Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study
Eustachio Nettis, Silvia Ferrucci, Michela Ortoncelli, et al.
Journal of Investigational Allergology and Clinical Immunology (2020) Vol. 32, Iss. 2, pp. 124-132
Open Access | Times Cited: 54
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study
Cataldo Patruno, Gabriella Fabbrocini, G. Longo, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 4, pp. 581-586
Closed Access | Times Cited: 50
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study
Andrea Chiricozzi, Niccolò Gori, Alessandra Narcisi, et al.
Drugs in R&D (2022) Vol. 22, Iss. 3, pp. 245-252
Open Access | Times Cited: 34
Dupilumab-associated ocular manifestations: A review of clinical presentations and management
Duoduo Wu, Benjamin S. Daniel, Andre Jun Xian Lai, et al.
Survey of Ophthalmology (2022) Vol. 67, Iss. 5, pp. 1419-1442
Closed Access | Times Cited: 24
Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
Silvia Ferrucci, Giovanni Casazza, Luisa Angileri, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 3, pp. 791-791
Open Access | Times Cited: 38
Efficacy and Safety of Dupilumab in the Treatment of Refractory Atopic Dermatitis in Older Adults: A Retrospective, Single-Center Study
Ren Cai, Jinwen Huang, Caifeng Chen, et al.
Drugs & Aging (2025)
Closed Access
Efficacy of dupilumab in atopic comorbidities associated with moderate‐to‐severe adult atopic dermatitis
Eustachio Nettis, Vincenzo Patella, Carla Lombardo, et al.
Allergy (2020) Vol. 75, Iss. 10, pp. 2653-2661
Closed Access | Times Cited: 28
Considerations for managing elderly patients with atopic dermatitis
Maddalena Napolitano, Luca Potestio, Mariateresa Nocerino, et al.
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 5, pp. 501-511
Closed Access | Times Cited: 3
Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study
Christine E. Jo, Jorge R. Georgakopoulos, Matthew Ladda, et al.
Journal of the American Academy of Dermatology (2020) Vol. 82, Iss. 6, pp. 1530-1532
Open Access | Times Cited: 27
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis
Maria Concetta Fargnoli, Maria Esposito, Silvia Ferrucci, et al.
Journal of Dermatological Treatment (2020) Vol. 33, Iss. 2, pp. 1146-1149
Open Access | Times Cited: 24
A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world
Dong Hyek Jang, Seok‐Jae Heo, Hyung Don Kook, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 22
Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre
Firas Constantin Kreeshan, Ali Al‐Janabi, Richard B. Warren, et al.
Dermatology and Therapy (2020) Vol. 11, Iss. 1, pp. 149-160
Open Access | Times Cited: 23
Therapeutic New Era for Atopic Dermatitis: Part 1. Biologics
Jiyoung Ahn, Yu Sung Choi, Eric L. Simpson
Annals of Dermatology (2021) Vol. 33, Iss. 1, pp. 1-1
Open Access | Times Cited: 18
Long‐term real‐world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above: Retrospective chart analysis from a single tertiary care center
Nisha V. Parmar, Mohamed Ahmed Abdula, Amani Al Falasi, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 5
Open Access | Times Cited: 13
Assessment of potential predictive factors of dupilumab response in patients with moderate‐to‐severe atopic dermatitis
Gemma Melé‐Ninot, Laia Curto‐Barredo, Montserrat Bonfill‐Ortí, et al.
Australasian Journal of Dermatology (2023) Vol. 65, Iss. 2, pp. 153-162
Open Access | Times Cited: 7
Efficacy of hydrotherapy, spa therapy, and balneotherapy for psoriasis and atopic dermatitis: a systematic review
Arezoo Moini Jazani, Mohammad Hossein Ayati, Ata Allah Nadiri, et al.
International Journal of Dermatology (2022) Vol. 62, Iss. 2, pp. 177-189
Closed Access | Times Cited: 12
Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis
Bruce Strober, Usha G. Mallya, Min Yang, et al.
JAMA Dermatology (2021) Vol. 158, Iss. 2, pp. 142-142
Closed Access | Times Cited: 14
Real‐World Experience of 3‐Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis
Hideyuki Nakajima, Masahiro Kamata, Yoshiki Okada, et al.
Experimental Dermatology (2024) Vol. 33, Iss. 11
Closed Access | Times Cited: 1
Medidas de los resultados percibidos por el paciente en estudios de vida real en dermatitis atópica en España: revisión sistemática de la literatura
José Carlos Armario Hita, Esther Artime, N. Vidal-Vilar, et al.
Actas Dermo-Sifiliográficas (2022) Vol. 113, Iss. 7, pp. 685-704
Open Access | Times Cited: 6
Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience
Álvaro Martínez‐Doménech, V. Zaragozá-Ninet, A. Esteve-Martínez, et al.
Actas Dermo-Sifiliográficas (2023) Vol. 115, Iss. 2, pp. 150-158
Open Access | Times Cited: 2
Analysis of non‐responders to dupilumab in clinical practice: a cohort study
C. Linder, Jason Shourick, A.T. Touhouche, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 35, Iss. 3
Closed Access | Times Cited: 4
Effectiveness and safety of dupilumab in adults with moderate and severe atopic dermatitis in Colombia: Real-life experience
Julián Esteban Londoño Hernández, Lucía Cecilia Pérez, Sergio Moreno, et al.
World Allergy Organization Journal (2023) Vol. 16, Iss. 4, pp. 100763-100763
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top